Spots Global Cancer Trial Database for An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
Official Title: An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Study ID: NCT00980018
Conditions
Interventions
Study Description
Brief Summary: The purpose of this exploratory study will be to examine changes in chronic low grade chronic adverse events, measured by Common Terminology Criteria for Adverse Events (CTCAE) grading, when patients are switched from imatinib to nilotinib therapy.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Highlands Oncology Group, Fayetteville, Arkansas, United States
Hematology Oncology Services of Arkansas SC, Little Rock, Arkansas, United States
USC Norris Cancer Center LAC & USC Medical Center, Los Angeles, California, United States
Southwest Cancer Care Murrieta, Poway, California, United States
Rocky Mountain Cancer Centers RMCC - Aurora, Greenwood Village, Colorado, United States
Florida Cancer Institute, New Port Richey, Florida, United States
Cancer Centers of Florida PA Cancer Centers of FL-Orlando-4, Ocoee, Florida, United States
Stroger Cook County Hospital John H. Stroger Hospital, Chicago, Illinois, United States
St. Francis Hospital and Health Centers IndianaBlood&MarrowTransplantn, Beech Grove, Indiana, United States
St. Agnes Hospital, Baltimore, Maryland, United States
St. Louis University Cancer Center, Saint Louis, Missouri, United States
Northwest Cancer Specialists Salmon Creek Office, Portland, Oregon, United States
Oregon Health Sciences University, Portland, Oregon, United States
The Jones Clinic, Germantown, Tennessee, United States
Texas Oncology, P.A., Bedford, Texas, United States
Presbyterian Hospital of Dallas TexasOncology@PresbyterianHosp, Dallas, Texas, United States
Texas Oncology Texas Oncology - Sugar Land, Dallas, Texas, United States
MD Anderson Cancer Center/University of Texas, Houston, Texas, United States
Cancer Care Centers of South Texas / HOAST CCC of So. TX- San Antonio(2), San Antonio, Texas, United States
Novartis Investigative Site, Brampton, Ontario, Canada
Novartis Investigative Site, Toronto, Ontario, Canada
Novartis Investigative Site, Montreal, Quebec, Canada
Novartis Investigative Site, Montreal, Quebec, Canada
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
